Lupin Launches Generic Drug To Treat Wilsons Disease In US Market
Drug major Lupin on Tuesday said it has launched Penicillamine tablets, used to treat Wilson's disease, in the US market. The company has launched a generic product in the market after having received approval from the US and Drug Administration (U.S.FDA) earlier.The Mumbai-based drug firm's product is the generic equivalent of Mylan Specialty's Depen tablets, which are indicated for the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.As IQVIA MAT December 2020 data, Penicillamine tablets had estimated annual sales of USD 5 million in the US market. Wilson's disease is a genetic disorder that causes too much copper accumulation in organs.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
